Core Viewpoint - Vivani Medical, Inc. is advancing its innovative miniature drug implants aimed at improving patient adherence in chronic disease treatment, particularly in the GLP-1 drug class [1][4][5] Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing ultra long-acting drug implants using its proprietary NanoPortal™ technology [1][4] - The company's lead programs include NPM-115 (exenatide implant) for weight management and NPM-139 (semaglutide implant) for chronic weight management, both designed for infrequent administration [4] Upcoming Events - CEO Adam Mendelsohn will present at the AAPS workshop on May 14, 2025, discussing advances in drug delivery and patient adherence [2][3] - The presentation will focus on the company's lead program, NPM-115, with results from the LIBERATE-1™ study expected this year [2] Industry Context - Medication non-adherence affects approximately 50% of patients, contributing to over $500 billion in avoidable healthcare costs and 125,000 preventable deaths annually in the U.S. [5] - The current GLP-1 landscape includes over 50 new molecular entities in clinical development, highlighting the competitive environment in which Vivani operates [5]

Core Viewpoint - Vivani Medical, Inc. is advancing its miniature, ultra long-acting drug implants aimed at improving patient adherence in chronic disease treatment, particularly in the GLP-1 drug class [1][4][5] Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic implants using its proprietary NanoPortal™ technology [4] - The company’s lead programs include NPM-115 (exenatide implant) and NPM-139 (semaglutide implant), designed for chronic weight management with administration once or twice a year [4] - Vivani is also developing NPM-119, a six-month GLP-1 implant for type 2 diabetes treatment [4] Upcoming Events - CEO Adam Mendelsohn will present on "Addressing Patient Adherence: Advances in Drug Delivery" at the AAPS workshop on May 14, 2025 [2] - A panel discussion featuring Dr. Mendelsohn will address key hurdles and trends in GLP-1 drug development on the same day [3] Market Context - Medication non-adherence affects approximately 50% of patients, contributing to over $500 billion in annual avoidable healthcare costs and 125,000 preventable deaths in the U.S. [5] - The current GLP-1 landscape includes over 50 new molecular entities in clinical development, positioning Vivani's differentiated portfolio as a potential attractive option for patients and healthcare providers [5]

Core Insights - Vivani Medical and Okava Pharmaceuticals are expanding their collaboration to develop OKV-119, a long-acting GLP-1 therapy for weight management and cardiometabolic conditions in dogs, building on their initial partnership focused on cats [1][3][4] Company Overview - Vivani Medical is a clinical-stage biopharmaceutical company specializing in miniature, ultra long-acting drug implants, utilizing its proprietary NanoPortal™ technology for steady drug delivery [1][5] - Okava Pharmaceuticals focuses on developing treatments for chronic diseases in aging dogs and cats, aiming to enhance the quality of veterinary care [1][8] Product Development - OKV-119 is designed to mimic the physiological effects of caloric restriction, improving insulin sensitivity and energy metabolism without altering feeding routines [3] - The product aims to address the issue of obesity in dogs, with over half of U.S. dogs classified as overweight or obese, which can lead to chronic diseases and reduced lifespans [3] Market Potential - The collaboration reflects a growing market for veterinary medicine, with Vivani's technology positioned to meet unmet needs and capture future value in this expanding industry segment [4] - Vivani's lead programs include NPM-139 and NPM-115, both GLP-1 implants for chronic weight management in humans, indicating a broader application of their technology [5][7] Financial Aspects - The financial terms of the expanded collaboration were not disclosed, but the partnership is structured to minimize costs and risks for Vivani while providing potential future milestone payments and royalties [4]